BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of BIOLASE (NASDAQ:BIOL) in a research note issued to investors on Sunday. The firm issued a sell rating on the medical technology company’s stock.

Several other research firms have also weighed in on BIOL. Benchmark restated a “speculative buy” rating and set a $0.40 target price on shares of BIOLASE in a report on Wednesday, October 2nd. Ascendiant Capital Markets decreased their price target on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd.

BIOLASE Price Performance

Shares of BIOL stock opened at $0.01 on Friday. The firm’s 50-day simple moving average is $0.01 and its 200-day simple moving average is $0.05. BIOLASE has a 1-year low of $0.02 and a 1-year high of $1.94. The firm has a market cap of $280,618.80, a P/E ratio of 0.00 and a beta of 0.67.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.